Global Hepatocellular Carcinoma Market Insights, Epidemiology & Market Forecast to 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Hepatocellular Carcinoma - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

Hepatocellular Carcinoma Epidemiology

The Hepatocellular Carcinoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Hepatocellular Carcinoma Drug Chapters

This segment of the Hepatocellular Carcinoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Hepatocellular Carcinoma Market Outlook

The Hepatocellular Carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Companies Mentioned

  • Bayer HealthCare
  • Sumitomo Dainippon Pharma
  • Bristol-Myers Squibb
  • Bayer Pharma
  • Merck/Eisai
  • Eli Lilly and Co.
  • Exelixis Inc.
  • Tiziana Life Sciences
  • Pfizer
  • CASI Pharmaceuticals

Key Topics Covered:

1. Key Insights

2. Hepatocellular Carcinoma Market Overview at a Glance

3. Disease Background and Overview: Hepatocellular Carcinoma

4. Epidemiology and Patient Population

5. Key Findings

6. Population and Forecast Parameters

7. Country Wise-Epidemiology of HCC

8. Treatment Practices

9. Unmet Needs

10. Marketed Drug Analysis

11. Emerging Therapies

12. Emerging Drugs Analysis

13. Other Promising Candidates

14. Failure in Phase III Clinical trials for Hepatocellular Carcinoma

15. Hepatocellular Carcinoma [HCC]: G8 Countries Market Analysis

16. Key Findings

17. Market Outlook by Country

18. Market Drivers

19. Market Barriers

20. Appendix

21. Report Methodology

22. Capabilities

23. Disclaimer

24. About the Publisher

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8w7n8l/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs